News

Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV. Scientists from the Oak Crest Institute of Science, in Pasadena, CA, report that they have developed a matchstick size implant, similar to a contraceptive implant, that successfully delivers a controlled, sustained release of ARV drugs for up to 40 days in dogs with no adverse side effects.

The month of May brings many things, among them Mother's Day, tulips, and Lyme Disease Awareness campaigns. But according to Dr. Richard S. Ostfeld, a disease ecologist at the Cary Institute of Ecosystem Studies in Millbrook, N.Y., if we want to get a leg up on tickborne illness we need to become vigilant earlier in the season.

Today’s healthcare industry has seen dramatic changes in the patient experience. The success of our advancements in healthcare and technology has created far more complex, chaotic interactions. From simple check-ups to operating room procedures, some might argue that today’s patient has become more of a number as opposed to a human being with personal preferences, feelings and emotions. Patient Experience Week (April 27-May 1, 2015) helps us to take a moment and center ourselves back to what is truly the heart of healthcare – care and compassion.

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study. While nearly all of the 398 hospitals in the study use a variety of measures to protect their patients from Clostridium difficile infections, 48 percent haven't adopted strict limits on the use of antibiotics and other drugs that can allow the dangerous bug to flourish, the researchers report.

Research from the University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.

Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa.

A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.